Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the... However, it is important to note that GHB is a designated Orphan drug (in 1985).
- Mechanism
- Curator reviewed
GHB is present at much higher concentrations in the brain, where it activates GABA-B receptors to exert its sedative effects. With high affinity, GHB binds to excitatory GHB receptors that are densely expressed throughout the brain, including the cotex and hippocampus. There is some evidence in research that upon activation of GHB receptors in some brain areas, the excitatory neurotransmitter glutamate is released. GHB stimulates dopamin release at low concentrations by acting on the GHB receptor, and the release of dopamine occurs in a biphasic manner. At higher concentrations, GHB inhibits dopamine release by acting on the GABA-B receptors, which is followed by GHB receptor signaling and increased release of dopamine. This explains the paradoxical mix of sedative and stimulatory properties of GHB, as well as the so-called "rebound" effect, experienced by individuals using GHB as a sleeping agent, wherein they awake suddenly after several hours of GHB-induced deep sleep. It is proposed that overtime, the level of GHB in the brain decreases below the threshold for significant GABA-B receptor activation, leading to preferential activation of GHB receptor over GABA-B receptors and enhanced wakefulness.
- Primary indication
- Gamma-hydroxybutyric acid is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged 7 years and older with narcolepsy, as well as idiopathic hypersomnia (IH) in...Curator reviewed · 3 structured indications
- Formula / weight
- C4H8O3 · 104.1045 g/mol (avg)
- First approval
- Canada, 2023 · United States, 2020
- Also known as
- 3-carboxypropoxy acid · 4-hydroxy-butyric acid · 4-hydroxybutanoate · 4-hydroxybutanoic acid · 4-Hydroxybutyric acid
- Brand names
- Xywav
Resolves to
SJZRECIVHVDYJC-UHFFFAOYSA-NSMILESOCCCC(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with gamma-Hydroxybutyric acid, and which of those have an active Phase 3 trial?